Dr Elizabeth Renzoni is consultant respiratory physician at Royal Brompton Hospital and honorary senior lecturer at imperial College, London.
Specialist clinical interests
Connective tissue disease-associated interstitial lung involvement
Idiopathic interstitial pneumonias
Sarcoidosis and hypersensitivity penumonitis, as well as the rarer entities including Langerhans’ cell histiocytsosis
Dr Renzoni's research has focused on the study of genetic associations with lung fibrosis, fibroblast gene expression of fibroblasts isolated from different patterns of lung fibrosis, vascular and lymphatic remodelling in idiopathic and scleroderma-associated lung fibrosis, and the study of the effects of supplemental oxygen in fibrotic lung diseases.
Dr Renzoni was trained in respiratory medicine at the University of Siena, Italy. In 1999 she was awarded an ERS research fellowship to study genetic predisposition to interstitial lung diseases at the Interstitial Lung Disease Unit at Royal Brompton Hospital. She subsequently continued research and clinical activites as a clinical research fellow in the Unit, and completed a PhD in gene expression analysis in pulmonary fibrosis with Imperial College. In 2006, she was appointed consultant physician in the Interstitial Lung Disease Unit at Royal Brompton Hospital.
She is frequently invited to speak at national and international scientific meetings.
- MBBS (Hons) (Italian equivalent), University of Siena
- Respiratory disease specialist (Hons); Italian equivalent of CCST
- PhD, Imperial College
Current membership of national and international societies
- Member, British Thoracic Society
- Member, European Respiratory Society
- Honorary faculty member of the PhD programme in cellular biology and physiopathology, University of Siena, Italy
Dr Renzoni has 46 papers published in PubMed on aspects of respiratory/interstitial lung diseases, and has written several book chapters on ILD and sarcoidosis. She regularly reviews research and clinical manuscripts for international journals.
Visca D, Montgomery A, de Lauretis A, Sestini P, Soteriou H, Maher TM, Athol Wells AU, Renzoni EA. Ambulatory oxygen in interstitial lung diseases. Eur Respir J, in press (Oct 2011).
de Lauretis A, Veeraraghavan S, Renzoni E. Review series: Aspects of
Interstitial lung disease: connective tissue disease-associated interstitial lung
disease: how does it differ from IPF? How should the clinical approach differ?
Chron Respir Dis. 2011;8:53-82.
Fonseca C, Abraham D, Renzoni EA. Endothelin in pulmonary fibrosis. Am J
Respir Cell Mol Biol. 2011;44:1-10.
Verma H, Nicholson AG, Kerr KM, Dempsey OJ, Gibbs AR, Campbell I, Black F,
Rassl D, Rice AJ, Renzoni EA, Wells AU, Hansell DM. Alveolar proteinosis with
hypersensitivity pneumonitis: a new clinical phenotype. Respirology. 2010;15:1197-202.
Rossi A, Sozio F, Sestini P, Renzoni EA, Khan K, Denton CP, Abraham DJ, Weber
E. Lymphatic and blood vessels in scleroderma skin, a morphometric analysis. Hum
Zappala CJ, Latsi PI, Nicholson AG, Colby TV, Cramer D, Renzoni EA, Hansell DM, du Bois RM, Wells AU. Marginal decline in forced vital capacity is associated with a poor outcome in idiopathic pulmonary fibrosis. Eur Respir J. 2010;35:830-6.
Corte TJ, Ellis R, Renzoni EA, Hansell DM, Nicholson AG, du Bois RM, Wells AU. Use of intravenous cyclophosphamide in known or suspected, advanced non-specific interstitial pneumonia. Sarcoidosis Vasc Diffuse Lung Dis. 2009;26:132-8.
Renzoni EA. Interstitial lung disease in systemic sclerosis. Monaldi Arch
Chest Dis. 2007 Dec;67(4):217-28.
Fonseca C, Lindahl GE, Ponticos M, Sestini P, Renzoni EA, Holmes AM, Spagnolo P, Pantelidis P, Leoni P, McHugh N, Stock CJ, Shi-Wen X, Denton CP, Black CM, Welsh KI, du Bois RM, Abraham DJ. A polymorphism in the CTGF promoter region associated with systemic sclerosis. N Engl J Med. 2007 20;357(12):1210-20.
Shi-wen X, Kennedy L, Renzoni EA, Bou-Gharios G, du Bois RM, Black CM, Denton CP, Abraham DJ, Leask A. Endothelin is a downstream mediator of profibrotic responses to transforming growth factor beta in human lung fibroblasts. Arthritis Rheum. 2007 Dec;56(12):4189-94.
Shi-Wen X, Renzoni EA, Kennedy L, Howat S, Chen Y, Pearson JD, Bou-Gharios G, Dashwood MR, du Bois RM, Black CM, Denton CP, Abraham DJ, Leask A. Endogenous endothelin-1 signaling contributes to type I collagen and CCN2 overexpression in fibrotic fibroblasts. Matrix Biol. 2007;26:625-32.